VCEL — Vericel Corp
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 887359 ·
Last close
$39.71
Market Cap
$2.03B
52W High
$49.32
52W Low
$28.95
ADV30
500,437
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 77,457,000 | 56,402,000 | 434,000 | 2,206,000 | 502,866,000 | 125,358,000 | 132,825,000 |
| Mar 2026 | 68,425,000 | 49,266,000 | -8,064,000 | -6,302,000 | 485,627,000 | 109,295,000 | 129,396,000 |
| Dec 2025 | 92,918,000 | 73,128,000 | 22,415,000 | 23,243,000 | 487,969,000 | 100,092,000 | 133,329,000 |
| Sep 2025 | 67,503,000 | 49,585,000 | 3,450,000 | 5,074,000 | 453,274,000 | 100,403,000 | 131,416,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$69,670,000
Investing CF
$-26,788,000
Financing CF
$1,944,000
CapEx
$-8,006,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.47
As of
2026-08-02
Balance + Analyst (yfinance extras)
Retained Earnings
$-380,393,000
Inventory
$18,382,000
Receivables
$75,712,000
ST Investments
$37,100,000
EBIT TTM
$25,720,000
Pretax Income TTM
$25,080,000
Interest Exp TTM
$640,000
Analysts
7
Yahoo Snapshot (yfinance, live)
Total Revenue
$306,303,008
EBITDA
$31,154,000
Free Cash Flow
$55,544,876
Enterprise Value
$1,893,936,640
Total Cash
$162,458,000
Total Debt
$93,133,000
Shares Out
51,206,614
Trailing EPS
$0.48
Book Value
$7.23
ROE
7.2%
ROA
2.4%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 276,259,000 | 11,044,000 | 16,518,000 | 487,969,000 | 133,329,000 | 354,640,000 | 51,910,000 |
| Dec 2024 | 237,224,000 | 4,519,000 | 10,362,000 | 432,722,000 | 140,755,000 | 291,967,000 | 58,163,000 |
| Dec 2023 | 197,516,000 | -6,464,000 | -3,182,000 | 353,657,000 | 127,705,000 | 225,952,000 | 35,311,000 |
| Dec 2022 | 164,365,000 | -17,058,000 | -16,709,000 | 273,003,000 | 80,731,000 | 192,272,000 | 17,687,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.85
Max Pain — expiry 2026-10-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $30.00 · spot: $40.73 · call volume: 15 · put volume: 5
Expected Move to 2026-10-16:
±$5.28
(12.95%) —
implied range
$35.45 –
$46.00
· ATM straddle on $40.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| KOD | Kodiak Sciences Inc. | $2.03B | $32.35 | — |
| ALVO | Alvotech | $2.05B | $5.75 | — |
| RXRX | RECURSION PHARMACEUTICALS, INC. | $2.00B | $3.74 | — |
| ADMA | ADMA BIOLOGICS, INC. | $2.10B | $9.38 | — |
| MESO | MESOBLAST LTD | $1.96B | $15.12 | — |
News headlines (Yahoo Finance, 1h cache)
Vericel (VCEL) Stock Looks Fully Priced After A 31% Gain
2026-09-26 22:06 · Yahoo
Vericel to Present at the 24th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 15, 2026
2026-09-08 12:30 · Yahoo
Vericel Q2 Earnings Call Highlights
2026-07-30 21:03 · Yahoo
Vericel to Report Second Quarter 2026 Financial Results on July 30, 2026
2026-07-16 12:30 · Yahoo
Vericel Revenue Jumped 20%. One Biotech Investor Just Reported Adding $63 Million More
2026-05-30 18:59 · Yahoo
MediWound Reports Second Quarter 2026 Financial Results and Provides Corporate Update
2026-08-13 11:00 · Yahoo
Next GLP-1 Billion-Dollar Market: Fireside Chat with Conexeu Sciences CEO Miles Harrison
2026-08-03 14:55 · Yahoo
Vericel Corporation (VCEL) Beats Q2 Earnings and Revenue Estimates
2026-07-30 13:35 · Yahoo
Vericel Reports Second Quarter 2026 Financial Results, Raises Full-Year Financial Guidance and Announces Share Repurchase Program
2026-07-30 11:55 · Yahoo
Vericel Stock Is Up 10%. Here's What This $402,000 Insider Sale Really Suggests
2026-06-27 17:18 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.